Buccal insulin for the management of type 1 diabetes
Please note that this topic has now been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 311
- Referral date:
- 01 February 2010
- Topic area
- Endocrine, nutritional and metabolic
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- TBC
- Executive Lead:
- TBC
- Project manager:
- TBC
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 January 2024 | Discontinued. Please note that this topic has now been discontinued. |
| 28 July 2011 |
As you are aware, the Department of Health has asked us to carry out a single technology appraisal of buccal insulin within its licensed indication for the management of type 1 diabetes as part of our 22nd wave work programme. Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual